Genentech Expects Avastin Colon Cancer Data Ahead Of Schedule In 2009
This article was originally published in The Pink Sheet Daily
Executive Summary
Revised timeline for the C-08 trial does not change Genentech’s assessment of probability of success.
You may also be interested in...
Roche To Partner With Two European Biotechs On Oncology Candidate
Deal with BioInvent International and ThromboGenics will develop the novel monoclonal antibody TB-403.
Roche To Partner With Two European Biotechs On Oncology Candidate
Deal with BioInvent International and ThromboGenics will develop the novel monoclonal antibody TB-403.
Avastin Passes Tox Test In Colon Cancer
Drug and control arms in C-08 study of Genentech drug turn out the same.